China Pharma Sector Poised to Benefit From New Five-Year Plan -- Market Talk

Dow Jones10-29

0522 GMT - China's pharmaceutical industry is set to gain from Beijing's new five-year plan, which emphasizes innovation-driven growth and technological self-reliance, says BMI, a unit of Fitch Solutions. It expects the sector to accelerate innovation in high-value segments, while continuing regulatory reforms strengthen China's global competitiveness. "China-based drugmakers stand to benefit from faster approvals and clearer compliance pathways," BMI says in a note. It expects global drugmakers to increasingly enter licensing agreements with Chinese pharmaceutical companies, reflecting confidence in the market's advanced R&D capabilities and their demand for new drug assets. BMI projects China's pharmaceutical market to grow robustly through 2034, reaching $344 billion in value with a 5.6% CAGR in dollar terms. (jason.chau@wsj.com)

(END) Dow Jones Newswires

October 29, 2025 01:22 ET (05:22 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579947634?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 13:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579947634","market":"fut","top_or_hot":-1,"title":"China Pharma Sector Poised to Benefit From New Five-Year Plan -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0522 GMT - China's pharmaceutical industry is set to gain from Beijing's new five-year plan, which emphasizes innovation-driven growth and technological self-reliance, says BMI, a unit of Fitch Solutions. It expects the sector to accelerate innovation in high-value segments, while continuing regulatory reforms strengthen China's global competitiveness. \"China-based drugmakers stand to benefit from faster approvals and clearer compliance pathways,\" BMI says in a note. It expects global drugmakers to increasingly enter licensing agreements with Chinese pharmaceutical companies, reflecting confidence in the market's advanced R&amp;D capabilities and their demand for new drug assets. BMI projects China's pharmaceutical market to grow robustly through 2034, reaching $344 billion in value with a 5.6% CAGR in dollar terms. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 29, 2025 01:22 ET (05:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Pharma Sector Poised to Benefit From New Five-Year Plan -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Pharma Sector Poised to Benefit From New Five-Year Plan -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-29 13:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0522 GMT - China's pharmaceutical industry is set to gain from Beijing's new five-year plan, which emphasizes innovation-driven growth and technological self-reliance, says BMI, a unit of Fitch Solutions. It expects the sector to accelerate innovation in high-value segments, while continuing regulatory reforms strengthen China's global competitiveness. \"China-based drugmakers stand to benefit from faster approvals and clearer compliance pathways,\" BMI says in a note. It expects global drugmakers to increasingly enter licensing agreements with Chinese pharmaceutical companies, reflecting confidence in the market's advanced R&amp;D capabilities and their demand for new drug assets. BMI projects China's pharmaceutical market to grow robustly through 2034, reaching $344 billion in value with a 5.6% CAGR in dollar terms. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 29, 2025 01:22 ET (05:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CPHI","symbol_name":"惠普森医药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2579947634","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579947634","pubTimestamp":1761715320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0522 GMT - China's pharmaceutical industry is set to gain from Beijing's new five-year plan, which emphasizes innovation-driven growth and technological self-reliance, says BMI, a unit of Fitch Solutions. It expects the sector to accelerate innovation in high-value segments, while continuing regulatory reforms strengthen China's global competitiveness. \"China-based drugmakers stand to benefit from faster approvals and clearer compliance pathways,\" BMI says in a note. It expects global drugmakers to increasingly enter licensing agreements with Chinese pharmaceutical companies, reflecting confidence in the market's advanced R&D capabilities and their demand for new drug assets. BMI projects China's pharmaceutical market to grow robustly through 2034, reaching $344 billion in value with a 5.6% CAGR in dollar terms. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CPHI":"惠普森医药","BK4007":"制药"},"translate_title":"中国制药行业有望受益于新五年计划——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPHI":1.5},"content_text":"0522 GMT - China's pharmaceutical industry is set to gain from Beijing's new five-year plan, which emphasizes innovation-driven growth and technological self-reliance, says BMI, a unit of Fitch Solutions. It expects the sector to accelerate innovation in high-value segments, while continuing regulatory reforms strengthen China's global competitiveness. \"China-based drugmakers stand to benefit from faster approvals and clearer compliance pathways,\" BMI says in a note. It expects global drugmakers to increasingly enter licensing agreements with Chinese pharmaceutical companies, reflecting confidence in the market's advanced R&D capabilities and their demand for new drug assets. BMI projects China's pharmaceutical market to grow robustly through 2034, reaching $344 billion in value with a 5.6% CAGR in dollar terms. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 29, 2025 01:22 ET (05:22 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579947634","isCrawlerRequest":true}